Related Experiment Video

Updated: Oct 11, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Marked and prompt hemodynamic improvement by carperitide in refractory congestive heart failure due to dilated

M Kikuchi1, M Nakamura, T Suzuki

  • 1Second Department of Internal Medicine, School of Medicine, Iwate Medical University, Japan.

Japanese Heart Journal
|October 21, 2000
PubMed

Insights

Carperitide, a synthetic atrial natriuretic peptide, effectively treated a young patient with refractory congestive heart failure (CHF). This peptide improved cardiac function and hemodynamic parameters without adverse effects, offering a new therapeutic option for severe CHF.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) in adolescents can be challenging to manage.
  • Dilated cardiomyopathy presents a significant risk for low output syndrome.
  • Conventional intensive treatments may not always suffice for refractory cases.

Observation:

  • A 16-year-old male with dilated cardiomyopathy and CHF developed low output syndrome despite intensive therapy.
  • The patient exhibited hyponatremia and hypochloremia, indicating severe cardiac compromise.
  • Intravenous carperitide (synthetic atrial natriuretic peptide) was administered as an adjunct therapy.

Findings:

  • Carperitide administration led to prompt and dramatic improvement in the patient's symptoms and hemodynamic parameters.
  • The therapeutic benefits persisted for over 20 days without evidence of drug intolerance.
  • Significant diuresis was not observed, suggesting a mechanism beyond simple fluid removal.

Implications:

  • Carperitide may be a safe and effective option for reducing cardiac preload in refractory CHF patients.
  • This treatment can be beneficial when conventional intensive therapies have been maximized.
  • Further research into carperitide's role in pediatric and adolescent refractory CHF is warranted.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...